Sarepta Therapeutics (SRPT) estimates total net product revenue of $369.6M ($380.61M estimated) for Q4 and $1.86B ($2.12B estimated) for full-year 2025.
Elevidys (delandistrogene moxeparvovec), the firm’s gene therapy indicated for the treatment of ambulatory patients 4 years of age and older with